Serum biomarkers of brain injury may be able to help measure and classify neurologic injury in children with cardiac arrest (CA), according to an article recently published by Dr. Ericka Fink in the journal Critical Care Medicine. In two studies conducted at the Children’s Hospital of Pittsburgh, Fink's research team examined the time course of serum neuron-specific enolase (NSE), astorcyte (S100b), and axon (MBP) levels in children during the first week after CA and tested the accuracy of serum and clinical biomarkers to classify favorable versus unfavorable outcome at 6 months. Her data indicate that these serum biomarkers could potentially aid in treatment decision making and outcome classification of children surviving pediatric CA. Dr. Fink is currently using these biomarkers in an NICHD/NIH funded study of the effect of the use of therapeutic hypothermia after CA in children. She is an Assistant Professor of Critical Care in Pediatrics at the Children’s Hospital of Pittsburgh, and a research scientist at the Safar Center for Resuscitation Research. Read the full abstract of the article here.